Clinical and Experimental Reproductive Medicine

  • 제44권4호
  • /
  • Pages.159-170
  • /
  • 2017
  • /
  • 2233-8233(pISSN)
  • /
  • 2233-8241(eISSN)
대한생식의학회 (The Korean Society for Reproductive Medicine)
권호 표지
DOI QR코드

DOI QR Code

Developing a deeper insight into reproductive biomarkers

  • Wahid, Braira (Centre for Applied Molecular Biology, University of the Punjab) ;
  • Bashir, Hamid (Centre for Applied Molecular Biology, University of the Punjab) ;
  • Bilal, Muhammad (Centre for Applied Molecular Biology, University of the Punjab) ;
  • Wahid, Khansa (Lahore College for Women University) ;
  • Sumrin, Aleena (Centre for Applied Molecular Biology, University of the Punjab)
  • 투고 : 2017.03.01
  • 심사 : 2017.11.20
  • 발행 : 2017.12.31
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

The development of biomarkers of reproductive medicine is still in its infancy because many black boxes are still present in reproductive medicine. Novel approaches to human infertility diagnostics and treatment must be developed because reproductive medicine has lagged behind in the implementation of biomarkers in clinical medicine. Despite the dearth of the available literature, the current rapid pace of publications suggests that this gap will soon be filled therefore; this review is a $pr\acute{e}cis$ of the research that has been done so far and will provide a basis for the development of biomarkers in reproductive medicine.

키워드

참고문헌

  1. Palmer SS, Barnhart KT. Biomarkers in reproductive medicine: the promise, and can it be fulfilled? Fertil Steril 2013;99:954-62. https://doi.org/10.1016/j.fertnstert.2012.11.019
  2. Centers for Disease Control and Prevention. National Center for Health Statistics: 2013 [Internet]. Atlanta: Centers for Disease Control and Prevention; 2016 [cited 2017 Dec 9]. Available from: http://www.cdc.gov/nchs/fastats/infertility.htm.
  3. Boivin J, Bunting L, Collins JA, Nygren KG. International estimates of infertility prevalence and treatment-seeking: potential need and demand for infertility medical care. Hum Reprod 2007;22:1506-12. https://doi.org/10.1093/humrep/dem046
  4. Iatropoulos MJ, Williams GM. Proliferation markers. Exp Toxicol Pathol 1996;48:175-81. https://doi.org/10.1016/S0940-2993(96)80039-X
  5. Poirier MC, Weston A. Human DNA adduct measurements: state of the art. Environ Health Perspect 1996;104 Suppl 5:883-93. https://doi.org/10.1289/ehp.96104s5883
  6. Samaha HS, Kelloff GJ, Steele V, Rao CV, Reddy BS. Modulation of apoptosis by sulindac, curcumin, phenylethyl-3-methylcaffeate, and 6-phenylhexyl isothiocyanate: apoptotic index as a biomarker in colon cancer chemoprevention and promotion. Cancer Res 1997;57:1301-5.
  7. Lucas JN. Chromosome translocations: a biomarker for retrospective biodosimetry. Environ Health Perspect 1997;105 Suppl 6:1433-6. https://doi.org/10.1289/ehp.97105s61433
  8. Chen WL, Sheets JJ, Nolan RJ, Mattsson JL. Human red blood cell acetylcholinesterase inhibition as the appropriate and conservative surrogate endpoint for establishing chlorpyrifos reference dose. Regul Toxicol Pharmacol 1999;29:15-22. https://doi.org/10.1006/rtph.1998.1256
  9. Schoket B, Poirier MC, Mayer G, Torok G, Kolozsi-Ringelhann A, Bognar G, et al. Biomonitoring of human genotoxicity induced by complex occupational exposures. Mutat Res 1999;445:193-203. https://doi.org/10.1016/S1383-5718(99)00126-6
  10. Thomas RS, Rank DR, Penn SG, Zastrow GM, Hayes KR, Pande K, et al. Identification of toxicologically predictive gene sets using cDNA microarrays. Mol Pharmacol 2001;60:1189-94. https://doi.org/10.1124/mol.60.6.1189
  11. Riggins GJ. Using serial analysis of gene expression to identify tumor markers and antigens. Dis Markers 2001;17:41-8. https://doi.org/10.1155/2001/185929
  12. Hecht SS. Human urinary carcinogen metabolites: biomarkers for investigating tobacco and cancer. Carcinogenesis 2002;23:907-22. https://doi.org/10.1093/carcin/23.6.907
  13. Anderson SL. 2001 Progress report: a western center for estuarine indicators research which will develop indicators of wetlands ecosystem health. Santa Barbara: Pacific Estuarine Ecosystem Indicator Research (PEEIR) Consortium; 2004.
  14. Rockett JC, Lynch CD, Buck GM. Biomarkers for assessing reproductive development and health. Part 1: pubertal development. Environ Health Perspect 2004;112:105-12.
  15. Pedersen JF, Ruge S. Serum level of secretory endometrial protein PP-14 in intact ectopic pregnancy. Br J Obstet Gynaecol 1991;98:414. https://doi.org/10.1111/j.1471-0528.1991.tb13438.x
  16. Anand-Ivell R, Dai Y, Ivell R. Neohormones as biomarkers of reproductive health. Fertil Steril 2013;99:1153-60. https://doi.org/10.1016/j.fertnstert.2012.12.023
  17. Rapino C, Battista N, Bari M, Maccarrone M. Endocannabinoids as biomarkers of human reproduction. Hum Reprod Update 2014;20:501-16. https://doi.org/10.1093/humupd/dmu004
  18. Matias I, Gatta-Cherifi B, Tabarin A, Clark S, Leste-Lasserre T, Marsicano G, et al. Endocannabinoids measurement in human saliva as potential biomarker of obesity. PLoS One 2012;7:e42399. https://doi.org/10.1371/journal.pone.0042399
  19. Drabovich AP, Dimitromanolakis A, Saraon P, Soosaipillai A, Batruch I, Mullen B, et al. Differential diagnosis of azoospermia with proteomic biomarkers ECM1 and TEX101 quantified in seminal plasma. Sci Transl Med 2013;5:212ra160. https://doi.org/10.1126/scitranslmed.3006260
  20. Malcher A, Rozwadowska N, Stokowy T, Kolanowski T, Jedrzejczak P, Zietkowiak W, et al. Potential biomarkers of nonobstructive azoospermia identified in microarray gene expression analysis. Fertil Steril 2013;100:1686-94.e1-7. https://doi.org/10.1016/j.fertnstert.2013.07.1999
  21. Specht IO, Toft G, Hougaard KS, Lindh CH, Lenters V, Jonsson BA, et al. Associations between serum phthalates and biomarkers of reproductive function in 589 adult men. Environ Int 2014;66:146-56. https://doi.org/10.1016/j.envint.2014.02.002
  22. Pan Y, Jing J, Dong F, Yao Q, Zhang W, Zhang H, et al. Association between phthalate metabolites and biomarkers of reproductive function in 1066 Chinese men of reproductive age. J Hazard Mater 2015;300:729-36. https://doi.org/10.1016/j.jhazmat.2015.08.011
  23. El Melegy NT, Aboulella HA, Abul-Fadl AM, Mohamed NA. Potential biomarkers for differentiation of benign prostatic hyperplasia and prostate cancer. Br J Biomed Sci 2010;67:109-12. https://doi.org/10.1080/09674845.2010.11730306
  24. Esteves SC, Gosalvez J, Lopez-Fernandez C, Nunez-Calonge R, Caballero P, Agarwal A, et al. Diagnostic accuracy of sperm DNA degradation index (DDSi) as a potential noninvasive biomarker to identify men with varicocele-associated infertility. Int Urol Nephrol 2015;47:1471-7. https://doi.org/10.1007/s11255-015-1053-6
  25. Drabovich AP, Saraon P, Jarvi K, Diamandis EP. Seminal plasma as a diagnostic fluid for male reproductive system disorders. Nat Rev Urol 2014;11:278-88. https://doi.org/10.1038/nrurol.2014.74
  26. Vujovic S. Aetiology of premature ovarian failure. Menopause Int 2009;15:72-5. https://doi.org/10.1258/mi.2009.009020
  27. Iino K, Tarakida A, Abe K, Taniguchi R, Higuchi T, Takahashi I, et al. Role of antimullerian hormone as a biomarker of the menopausal transition. Menopause 2013;20:218-22.
  28. Lin PY, Huang FJ, Kung FT, Chiang HJ, Lin YJ, Lin YC, et al. Evaluation of serum anti-Mullerian hormone as a biomarker of early ovarian aging in young women undergoing IVF/ICSI cycle. Int J Clin Exp Pathol 2014;7:6245-53.
  29. Jiang L, Li W, Wu M, Cao S. Ciculating miRNA-21 as a biomarker predicts polycystic ovary syndrome (PCOS) in patients. Clin Lab 2015;61:1009-15.
  30. Shen SH, Shen SY, Liou TH, Hsu MI, Chang YC, Cheng CY, et al. Obesity and inflammatory biomarkers in women with polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol 2015;192:66-71. https://doi.org/10.1016/j.ejogrb.2015.06.022
  31. Zheng W, Yi X, Fadare O, Liang SX, Martel M, Schwartz PE, et al. The oncofetal protein IMP3: a novel biomarker for endometrial serous carcinoma. Am J Surg Pathol 2008;32:304-15. https://doi.org/10.1097/PAS.0b013e3181483ff8
  32. Lai HC, Wang YC, Yu MH, Huang RL, Yuan CC, Chen KJ, et al. DNA methylation as a biomarker for the detection of hidden carcinoma in endometrial atypical hyperplasia. Gynecol Oncol 2014;135:552-9. https://doi.org/10.1016/j.ygyno.2014.10.018
  33. Short RV. Progesterone in blood: I. the chemical determination of progesterone in peripheral blood. J Endocrinol 1958;16:415-25. https://doi.org/10.1677/joe.0.0160415
  34. Tamby Raja RL, Anderson AB, Turnbull AC. Endocrine changes in premature labour. Br Med J 1974;4:67-71. https://doi.org/10.1136/bmj.4.5936.67
  35. TambyRaja RL, Turnbull AC, Ratnam SS. Predictive oestradiol surge of premature labour and its suppression by glucocorticoids. Aust N Z J Obstet Gynaecol 1975;15:191-203. https://doi.org/10.1111/j.1479-828X.1975.tb00753.x
  36. Erny R, Pigne A, Prouvost C, Gamerre M, Malet C, Serment H, et al. The effects of oral administration of progesterone for premature labor. Am J Obstet Gynecol 1986;154:525-9. https://doi.org/10.1016/0002-9378(86)90595-8
  37. Meis PJ; Society for Maternal-Fetal Medicine. 17 Hydroxyprogesterone for the prevention of preterm delivery. Obstet Gynecol 2005;105(5 Pt 1):1128-35. https://doi.org/10.1097/01.AOG.0000160432.95395.8f
  38. Phipps MG, Hogan JW, Peipert JF, Lambert-Messerlian GM, Canick JA, Seifer DB. Progesterone, inhibin, and hCG multiple marker strategy to differentiate viable from nonviable pregnancies. Obstet Gynecol 2000;95:227-31.
  39. Meulenberg EP. Salivary progesterone as a biomarker in pregnancy. Biochem Anal Biochem 2015;4:188. https://doi.org/10.4172/2161-1009.1000188.
  40. Sieh W, Kobel M, Longacre TA, Bowtell DD, deFazio A, Goodman MT, et al. Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study. Lancet Oncol 2013;14:853-62. https://doi.org/10.1016/S1470-2045(13)70253-5
  41. Robertson DM, Oehler MK. Emerging role of inhibin as a biomarker for ovarian cancer. Womens Health (Lond) 2005;1:51-7. https://doi.org/10.2217/17455057.1.1.51
  42. Healy DL, Burger HG, Mamers P, Jobling T, Bangah M, Quinn M, et al. Elevated serum inhibin concentrations in postmenopausal women with ovarian tumors. N Engl J Med 1993;329:1539-42. https://doi.org/10.1056/NEJM199311183292104
  43. Robertson DM, McNeilage J. Inhibins as biomarkers for reproductive cancers. Semin Reprod Med 2004;22:219-25. https://doi.org/10.1055/s-2004-831897
  44. Yamashita K, Yamoto M, Shikone T, Minami S, Imai M, Nishimori K, et al. Production of inhibin A and inhibin B in human ovarian sex cord stromal tumors. Am J Obstet Gynecol 1997;177:1450-7. https://doi.org/10.1016/S0002-9378(97)70090-5
  45. Stewart J, Turner KJ. Inhibin B as a potential biomarker of testicular toxicity. Cancer Biomark 2005;1:75-91. https://doi.org/10.3233/CBM-2005-1109
  46. Moffit JS, Her LS, Mineo AM, Knight BL, Phillips JA, Thibodeau MS. Assessment of inhibin B as a biomarker of testicular injury following administration of carbendazim, cetrorelix, or 1,2-dibromo-3-chloropropane in Wistar han rats. Birth Defects Res B Dev Reprod Toxicol 2013;98:17-28. https://doi.org/10.1002/bdrb.21045
  47. Weiss G, O'Byrne EM, Steinetz BG. Relaxin: a product of the human corpus luteum of pregnancy. Science 1976;194:948-9. https://doi.org/10.1126/science.982052
  48. Szlachter BN, Quagliarello J, Jewelewicz R, Osathanondh R, Spellacy WN, Weiss G. Relaxin in normal and pathogenic pregnancies. Obstet Gynecol 1982;59:167-70.
  49. Garcia A, Skurnick JH, Goldsmith LT, Emmi A, Weiss G. Human chorionic gonadotropin and relaxin concentrations in early ectopic and normal pregnancies. Obstet Gynecol 1990;75:779-83.
  50. Jan Danser AH. Renin and prorenin as biomarkers in hypertension. Curr Opin Nephrol Hypertens 2012;21:508-14. https://doi.org/10.1097/MNH.0b013e32835623aa
  51. Witt BR, Wolf GC, Wainwright CJ, Johnston PD, Thorneycroft IH. Relaxin, CA-125, progesterone, estradiol, Schwangerschaft protein, and human chorionic gonadotropin as predictors of outcome in threatened and nonthreatened pregnancies. Fertil Steril 1990;53:1029-36. https://doi.org/10.1016/S0015-0282(16)53580-8
  52. Cartwright J, Duncan WC, Critchley HO, Horne AW. Serum biomarkers of tubal ectopic pregnancy: current candidates and future possibilities. Reproduction 2009;138:9-22. https://doi.org/10.1530/REP-09-0060
  53. Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z. Vascular endothelial growth factor (VEGF) and its receptors. Faseb J 1999;13:9-22. https://doi.org/10.1096/fasebj.13.1.9
  54. Fraser HM, Wilson H, Silvestri A, Morris KD, Wiegand SJ. The role of vascular endothelial growth factor and estradiol in the regulation of endometrial angiogenesis and cell proliferation in the marmoset. Endocrinology 2008;149:4413-20. https://doi.org/10.1210/en.2008-0325
  55. Fraser HM, Duncan WC. Vascular morphogenesis in the primate ovary. Angiogenesis 2005;8:101-16. https://doi.org/10.1007/s10456-005-9004-y
  56. Ladoux A, Frelin C. Hypoxia is a strong inducer of vascular endothelial growth factor mRNA expression in the heart. Biochem Biophys Res Commun 1993;195:1005-10. https://doi.org/10.1006/bbrc.1993.2144
  57. Daniel Y, Geva E, Lerner-Geva L, Eshed-Englender T, Gamzu R, Lessing JB, et al. Levels of vascular endothelial growth factor are elevated in patients with ectopic pregnancy: is this a novel marker? Fertil Steril 1999;72:1013-7. https://doi.org/10.1016/S0015-0282(99)00417-3
  58. Salven P, Manpaa H, Orpana A, Alitalo K, Joensuu H. Serum vascular endothelial growth factor is often elevated in disseminated cancer. Clin Cancer Res 1997;3:647-51.
  59. Vodolazkaia A, Yesilyurt BT, Kyama CM, Bokor A, Schols D, Huskens D, et al. Vascular endothelial growth factor pathway in endometriosis: genetic variants and plasma biomarkers. Fertil Steril 2016;105:988-96. https://doi.org/10.1016/j.fertnstert.2015.12.016
  60. Srivastava VK, Gara RK, Rastogi N, Mishra DP, Ahmed MK, Gupta S, et al. Serum vascular endothelial growth factor-A (VEGF-A) as a biomarker in squamous cell carcinoma of head and neck patients undergoing chemoradiotherapy. Asian Pac J Cancer Prev 2014;15:3261-5. https://doi.org/10.7314/APJCP.2014.15.7.3261
  61. Carvalho AF, Kohler CA, McIntyre RS, Knochel C, Brunoni AR, Thase ME, et al. Peripheral vascular endothelial growth factor as a novel depression biomarker: a meta-analysis. Psychoneuroendocrinology 2015;62:18-26. https://doi.org/10.1016/j.psyneuen.2015.07.002
  62. Sisman AR, Kiray M, Camsari UM, Evren M, Ates M, Baykara B, et al. Potential novel biomarkers for diabetic testicular damage in streptozotocin-induced diabetic rats: nerve growth factor beta and vascular endothelial growth factor. Dis Markers 2014;2014:108106.
  63. Costa TN, Cassaro Strunz CM, Nicolau JC, Gutierrez PS. Comparison of MB fraction of creatine kinase mass and troponin I serum levels with necropsy findings in acute myocardial infarction. Am J Cardiol 2008;101:311-4. https://doi.org/10.1016/j.amjcard.2007.08.037
  64. Chandra L, Jain A. Maternal serum creatine kinase as a biochemical marker of tubal pregnancy. Int J Gynaecol Obstet 1995;49:21-3. https://doi.org/10.1016/0020-7292(95)02340-I
  65. Duncan WC, Sweeting VM, Cawood P, Illingworth PJ. Measurement of creatine kinase activity and diagnosis of ectopic pregnancy. Br J Obstet Gynaecol 1995;102:233-7. https://doi.org/10.1111/j.1471-0528.1995.tb09100.x
  66. Earl U, Wells M, Bulmer JN. Immunohistochemical characterisation of trophoblast antigens and secretory products in ectopic tubal pregnancy. Int J Gynecol Pathol 1986;5:132-42. https://doi.org/10.1097/00004347-198606000-00004
  67. Beer LA, Tang HY, Sriswasdi S, Barnhart KT, Speicher DW. Systematic discovery of ectopic pregnancy serum biomarkers using 3-D protein profiling coupled with label-free quantitation. J Proteome Res 2011;10:1126-38. https://doi.org/10.1021/pr1008866
  68. Gemmell RS. Pregnancy specific B1-glycoprotein in normal and complicated pregnancies. Med Lab Sci 1982;39:245-56.
  69. Handwerger S, Freemark M. The roles of placental growth hormone and placental lactogen in the regulation of human fetal growth and development. J Pediatr Endocrinol Metab 2000;13:343-56.
  70. Mueller MD, Raio L, Spoerri S, Ghezzi F, Dreher E, Bersinger NA. Novel placental and nonplacental serum markers in ectopic versus normal intrauterine pregnancy. Fertil Steril 2004;81:1106-11. https://doi.org/10.1016/j.fertnstert.2003.08.049
  71. Christiansen M, Sorensen TL, Norgaard-Pedersen B. Human placental lactogen is a first-trimester maternal serum marker of Down syndrome. Prenat Diagn 2007;27:1-5. https://doi.org/10.1002/pd.1600
  72. Rausch ME, Barnhart KT. Serum biomarkers for detecting ectopic pregnancy. Clin Obstet Gynecol 2012;55:418-23. https://doi.org/10.1097/GRF.0b013e31825109f6
  73. Seeber BE. What serial hCG can tell you, and cannot tell you, about an early pregnancy. Fertil Steril 2012;98:1074-7. https://doi.org/10.1016/j.fertnstert.2012.09.014
  74. Cole LA, Butler SA. Hyperglycosylated human chorionic gonadotropin and human chorionic gonadotropin free beta-subunit: tumor markers and tumor promoters. J Reprod Med 2008;53:499-512.
  75. Sisinni L, Landriscina M. The role of human chorionic gonadotropin as tumor marker: biochemical and clinical aspects. Adv Exp Med Biol 2015;867:159-76.
  76. Kharfi A, Giguere Y, De Grandpre P, Moutquin JM, Forest JC. Human chorionic gonadotropin (hCG) may be a marker of systemic oxidative stress in normotensive and preeclamptic term pregnancies. Clin Biochem 2005;38:717-21. https://doi.org/10.1016/j.clinbiochem.2005.04.011
  77. Munnangi S, Gross SJ, Madankumar R, Salcedo G, Reznik SE. Pregnancy associated plasma protein-A2: a novel biomarker for Down syndrome. Placenta 2014;35:900-6. https://doi.org/10.1016/j.placenta.2014.08.001
  78. Aitken DA, Wallace EM, Crossley JA, Swanston IA, van Pareren Y, van Maarle M, et al. Dimeric inhibin A as a marker for Down's syndrome in early pregnancy. N Engl J Med 1996;334:1231-6. https://doi.org/10.1056/NEJM199605093341904
  79. Kalousova M, Muravska A, Zima T. Pregnancy-associated plasma protein A (PAPP-A) and preeclampsia. Adv Clin Chem 2014;63:169-209.
  80. De Mees C, Bakker J, Szpirer J, Szpirer C. Alpha-fetoprotein: from a diagnostic biomarker to a key role in female fertility. Biomark Insights 2007;1:82-5.
  81. Newby D, Dalgliesh G, Lyall F, Aitken DA. Alphafetoprotein and alphafetoprotein receptor expression in the normal human placenta at term. Placenta 2005;26:190-200. https://doi.org/10.1016/j.placenta.2004.06.005
  82. Wald NJ, Huttly WJ, Hackshaw AK. Antenatal screening for Down's syndrome with the quadruple test. Lancet 2003;361:835-6. https://doi.org/10.1016/S0140-6736(03)12680-3
  83. Leighton PC, Kitau MJ, Chard T, Gordon YB, Leek AE. Levels of alpha-fetoprotein in maternal blood as a screening test for fetal neural-tube defect. Lancet 1975;2:1012-5.
  84. Cuckle HS, Wald NJ, Lindenbaum RH. Maternal serum alpha-fetoprotein measurement: a screening test for Down syndrome. Lancet 1984;1:926-9.
  85. Kamarainen M, Riittinen L, Seppala M, Palotie A, Andersson LC. Progesterone-associated endometrial protein: a constitutive marker of human erythroid precursors. Blood 1994;84:467-73.
  86. Wang P, Zhu L, Zhang X. The role of placental protein 14 in the pathogenesis of endometriosis. Reprod Sci 2013;20:1465-70. https://doi.org/10.1177/1933719113488452
  87. Bersinger NA, Birkhauser MH, Yared M, Wunder DM. Serum glycodelin pattern during the menstrual cycle in healthy young women. Acta Obstet Gynecol Scand 2009;88:1215-21. https://doi.org/10.3109/00016340903294264
  88. Wei Q, St Clair JB, Fu T, Stratton P, Nieman LK. Reduced expression of biomarkers associated with the implantation window in women with endometriosis. Fertil Steril 2009;91:1686-91. https://doi.org/10.1016/j.fertnstert.2008.02.121
  89. Lass A, Weiser W, Munafo A, Loumaye E. Leukemia inhibitory factor in human reproduction. Fertil Steril 2001;76:1091-6. https://doi.org/10.1016/S0015-0282(01)02878-3
  90. Senturk LM, Arici A. Leukemia inhibitory factor in human reproduction. Am J Reprod Immunol 1998;39:144-51. https://doi.org/10.1111/j.1600-0897.1998.tb00346.x
  91. Chen F, Ren P, Feng Y, Liu H, Sun Y, Liu Z, et al. Follistatin is a novel biomarker for lung adenocarcinoma in humans. PLoS One 2014;9:e111398. https://doi.org/10.1371/journal.pone.0111398
  92. Daponte A, Deligeoroglou E, Garas A, Pournaras S, Hadjichristodoulou C, Messinis IE. Activin A and follistatin as biomarkers for ectopic pregnancy and missed abortion. Dis Markers 2013;35:497-503. https://doi.org/10.1155/2013/969473
  93. Ramos IM, Podgaec S, Abrao MS, Oliveira Rd, Baracat EC. Evaluation of CA-125 and soluble CD-23 in patients with pelvic endometriosis: a case-control study. Rev Assoc Med Bras (1992) 2012;58:26-32. https://doi.org/10.1016/S0104-4230(12)70151-3
  94. Feeley KM, Wells M. Precursor lesions of ovarian epithelial malignancy. Histopathology 2001;38:87-95. https://doi.org/10.1046/j.1365-2559.2001.01042.x
  95. Bairey O, Blickstein D, Stark P, Prokocimer M, Nativ HM, Kirgner I, et al. Serum CA 125 as a prognostic factor in non-Hodgkin's lymphoma. Leuk Lymphoma 2003;44:1733-8. https://doi.org/10.1080/1042819031000104079
  96. Hedman M, Arnberg H, Wernlund J, Riska H, Brodin O. Tissue polypeptide antigen (TPA), hyaluronan and CA 125 as serum markers in malignant mesothelioma. Anticancer Res 2003;23:531-6.
  97. Whiteley MS, Marshall J. Raised serum CA125 level in leiomyoma and leiomyosarcoma of gastrointestinal origin. Br J Surg 1993;80:1551. https://doi.org/10.1002/bjs.1800801220
  98. Berruti A, Tampellini M, Torta M, Buniva T, Gorzegno G, Dogliotti L. Prognostic value in predicting overall survival of two mucinous markers: CA 15-3 and CA 125 in breast cancer patients at first relapse of disease. Eur J Cancer 1994;30:2082-4. https://doi.org/10.1016/0959-8049(94)00356-A
  99. Yamamoto M, Baba H, Toh Y, Okamura T, Maehara Y. Peritoneal lavage CEA/CA125 is a prognostic factor for gastric cancer patients. J Cancer Res Clin Oncol 2007;133:471-6. https://doi.org/10.1007/s00432-006-0189-2
  100. Bon GG, Kenemans P, Dekker JJ, Hompes PG, Verstraeten RA, van Kamp GJ, et al. Fluctuations in CA 125 and CA 15-3 serum concentrations during spontaneous ovulatory cycles. Hum Reprod 1999;14:566-70. https://doi.org/10.1093/humrep/14.2.566
  101. Kalambokis G, Kostoula A, Economou M, Tsianos EV. Tumor necrosis factor-alpha-related intraperitoneal release of CA 125 in cirrhotic patients with sterile ascites. Clin Chem 2005;51:2207-8. https://doi.org/10.1373/clinchem.2005.053058
  102. Kouris NT, Zacharos ID, Kontogianni DD, Goranitou GS, Sifaki MD, Grassos HE, et al. The significance of CA125 levels in patients with chronic congestive heart failure: correlation with clinical and echocardiographic parameters. Eur J Heart Fail 2005;7:199-203. https://doi.org/10.1016/j.ejheart.2004.07.015
  103. Bilgin T, Karabay A, Dolar E, Develioglu OH. Peritoneal tuberculosis with pelvic abdominal mass, ascites and elevated CA 125 mimicking advanced ovarian carcinoma: a series of 10 cases. Int J Gynecol Cancer 2001;11:290-4. https://doi.org/10.1046/j.1525-1438.2001.011004290.x
  104. Lotti F, Maggi M. Interleukin 8 and the male genital tract. J Reprod Immunol 2013;100:54-65. https://doi.org/10.1016/j.jri.2013.02.004
  105. Shahzad A, Knapp M, Lang I, Kohler G. Interleukin 8 (IL-8): a universal biomarker? Int Arch Med 2010;3:11. https://doi.org/10.1186/1755-7682-3-11
  106. Chutia H. Interleukin-6 (IL-6) as an alternative biomarker of carcinoma prostate. Int J Health Sci Res 2013;3:19-22.
  107. Tortorella C, Piazzolla G, Matteo M, Pinto V, Tinelli R, Sabba C, et al. Interleukin-6, interleukin-$1{\beta}$, and tumor necrosis factor ${\alpha}$ in menstrual effluents as biomarkers of chronic endometritis. Fertil Steril 2014;101:242-7. https://doi.org/10.1016/j.fertnstert.2013.09.041
  108. Wieser F, Fabjani G, Tempfer C, Schneeberger C, Zeillinger R, Huber JC, et al. Tumor necrosis factor-alpha promotor polymorphisms and endometriosis. J Soc Gynecol Investig 2002;9:313-8. https://doi.org/10.1177/107155760200900510
  109. Sikka SC, Wang R. Endocrine disruptors and estrogenic effects on male reproductive axis. Asian J Androl 2008;10:134-45. https://doi.org/10.1111/j.1745-7262.2008.00370.x
  110. Heikaus S, Winterhager E, Traub O, Grummer R. Responsiveness of endometrial genes Connexin26, Connexin43, C3 and clusterin to primary estrogen, selective estrogen receptor modulators, phyto- and xenoestrogens. J Mol Endocrinol 2002;29:239-49. https://doi.org/10.1677/jme.0.0290239
  111. Diel P, Schulz T, Smolnikar K, Strunck E, Vollmer G, Michna H. Ability of xeno- and phytoestrogens to modulate expression of estrogen-sensitive genes in rat uterus: estrogenicity profiles and uterotropic activity. J Steroid Biochem Mol Biol 2000;73:1-10. https://doi.org/10.1016/S0960-0760(00)00051-0
  112. Hopert AC, Beyer A, Frank K, Strunck E, Wunsche W, Vollmer G. Characterization of estrogenicity of phytoestrogens in an endometrial-derived experimental model. Environ Health Perspect 1998;106:581-6. https://doi.org/10.1289/ehp.98106581
  113. Cheek AO, Brouwer TH, Carroll S, Manning S, McLachlan JA, Brouwer M. Experimental evaluation of vitellogenin as a predictive biomarker for reproductive disruption. Environ Health Perspect 2001;109:681-90. https://doi.org/10.1289/ehp.01109s5681
  114. Tian H, Ru S, Wang Z, Cai W, Wang W. Estrogenic effects of monocrotophos evaluated by vitellogenin mRNA and protein induction in male goldfish (Carassius auratus). Comp Biochem Physiol C Toxicol Pharmacol 2009;150:231-6. https://doi.org/10.1016/j.cbpc.2009.04.014
  115. Henry TB, McPherson JT, Rogers ED, Heah TP, Hawkins SA, Layton AC, et al. Changes in the relative expression pattern of multiple vitellogenin genes in adult male and larval zebrafish exposed to exogenous estrogens. Comp Biochem Physiol A Mol Integr Physiol 2009;154:119-26. https://doi.org/10.1016/j.cbpa.2009.05.009
  116. Jung EM, An BS, Yang H, Choi KC, Jeung EB. Biomarker genes for detecting estrogenic activity of endocrine disruptors via estrogen receptors. Int J Environ Res Public Health 2012;9:698-711. https://doi.org/10.3390/ijerph9030698
  117. Jakowlew SB, Breathnach R, Jeltsch JM, Masiakowski P, Chambon P. Sequence of the pS2 mRNA induced by estrogen in the human breast cancer cell line MCF-7. Nucleic Acids Res 1984;12:2861-78. https://doi.org/10.1093/nar/12.6.2861
  118. Zajchowski DA, Sager R. Induction of estrogen-regulated genes differs in immortal and tumorigenic human mammary epithelial cells expressing a recombinant estrogen receptor. Mol Endocrinol 1991;5:1613-23. https://doi.org/10.1210/mend-5-11-1613
  119. Vivacqua A, Recchia AG, Fasanella G, Gabriele S, Carpino A, Rago V, et al. The food contaminants bisphenol A and 4-nonylphenol act as agonists for estrogen receptor alpha in MCF7 breast cancer cells. Endocrine 2003;22:275-84. https://doi.org/10.1385/ENDO:22:3:275
  120. Ren L, Marquardt MA, Lech JJ. Estrogenic effects of nonylphenol on pS2, ER and MUC1 gene expression in human breast cancer cells-MCF-7. Chem Biol Interact 1997;104:55-64. https://doi.org/10.1016/S0009-2797(97)03767-8
  121. Bagchi IC, Cheon YP, Li Q, Bagchi MK. Progesterone receptor-regulated gene networks in implantation. Front Biosci 2003;8:s852-61. https://doi.org/10.2741/1148
  122. Beyer C, Damm N, Brito V, Kuppers E. Developmental expression of progesterone receptor isoforms in the mouse midbrain. Neuroreport 2002;13:877-80. https://doi.org/10.1097/00001756-200205070-00028
  123. Sauter CN, McDermid RL, Weinberg AL, Greco TL, Xu X, Murdoch FE, et al. Differentiation of murine embryonic stem cells induces progesterone receptor gene expression. Exp Cell Res 2005;311: 251-64. https://doi.org/10.1016/j.yexcr.2005.09.005
  124. An BS, Choi KC, Kang SK, Hwang WS, Jeung EB. Novel calbindin-D(9k) protein as a useful biomarker for environmental estrogenic compounds in the uterus of immature rats. Reprod Toxicol 2003;17:311-9. https://doi.org/10.1016/S0890-6238(03)00003-0

피인용 문헌

  1. Novel affinity chromatography method for the efficient purification of recombinant Binder of SPerm homolog proteins vol.43, pp.17, 2017, https://doi.org/10.1002/jssc.202000250